Adverse reactions to accidental forearm injection of bacille Calmette-Guérin vaccine in schoolchildren: 12-Month cohort follow-up

Clinical Infectious Diseases

Volumn 38, Issue 10, 2004, Pages 1495-1497

  Gross, Samuel ^a   Kahan, Ernesto ^a,b   Vesterman, Liora ^a   Havkin, Dfra ^a   Leventhál, Alex ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b NONE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ISONIAZID; TUBERCULIN;

ARTICLE; BCG VACCINATION; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; FOREARM; HUMAN; INJECTION SITE; LYMPHADENITIS; MAJOR CLINICAL STUDY; MEDICATION ERROR; PAIN; PRIORITY JOURNAL; PRURITUS; SCHOOL CHILD; SIDE EFFECT; SKIN MANIFESTATION; SKIN SCAR; SKIN ULCER;

BCG VACCINE; CHILD; FOREARM; HUMANS; INCIDENCE; INJECTIONS, SUBCUTANEOUS; SKIN; SKIN TESTS;

EID: 2442641389     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/392505     Document Type: Article

References (24)

1. Price JF. BCG vaccination. Arch Dis Child 1982; 57:485-6.
2. Baily GV. Tuberculosis prevention Trial, Madras. Indian J Med Res 1980; 72(Suppl):1-74.
3. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta analysis of the published literature. JAMA 1994; 271:698-702.
4. Fine PE. BCG vaccination against tuberculosis and leprosy. Br Med Bull 1988; 44:691-703.
5. Bannon MY. BCG and tuberculosis. Arch Dis Child 1999; 80:80-8.
6. Hussey GD, Watkins MLV, Goddard EA, et al. Neonatal mycobacterial specific cytotoxic T-lymphocyte and cytokine profiles in response to distinct BCG vaccination strategies [letter]. Immunology 2002; 105: 314-24.
7. Arya SC. Disseminated bacille Calmette-Guerin disease after vaccination. Clin Infect Dis 1998; 26:774.
8. Lotte A, Wasz-Hockert O, Poisson N, Dumitrescu N, Verron M, Couvet E. BCG complications: estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Adv Tuberc Res 1984; 21:107-93.
9. Nyren M, Hagstromer L, Emtestam L. Instrumental measurement of the Mantoux test: differential effects of tuberculin and sodium lauryl sulfate on impedance response pattern in human skin. Dermatology 2000; 201:212-7.
10. [no author]. Inadvertent administration of BCG to school children. Commun Dis Rep CDR Wkly 1998; 8:439, 442.
11. Poliyel JM, Hughes A, Chiswick ML, Mughal MZ. Adverse local reactions from accidental BCG overdose in infants. BMJ 1996; 313:528-9.
12. Irvine KN. BCG and role vaccination: a practical handbook. London Association for the Prevention of Tuberculosis, 1957.
13. Kabra SK, Jain Y, Madhulika Seth V. BCG-associated adenitis [letter]. Lancet 1993; 341:970-1.
14. Turnbull FM, McIntyre PB, Achat HM, et al. National study of adverse reactions after vaccination with bacille Calmette-Guerin. Clin Infect Dis 2002; 34:447-53.
15. Sanders R, Dickson MG. BCG vaccination scars. BMJ 1982; 285: 1679-80.
16. Orges Gonzalez I. Prevalence of hypertrophic and keloid scars according to the site of administration of intradermal vaccine [in Spanish]. Bol Oficina Sanit Panam 1980; 88:481-8.
17. Chao CW. Post-vaccination keloid. Bull Int Union Tuberc 1972; 47(Suppl 2):178.
18. Ketchum LD, Cohen IK, Masters FW. Hypertrophic scars and keloids: a collective review. Plast Reconst Surg 1974; 53:140-54.
19. Oluwasanmi JO. Keloids in the African. Clin Plast Surg 1974; 1:179-95.
20. Caglayan S, Yegin O, Kayran K, Tomocin N, Kasirga E, Gun M. Is medical therapy effective for regional lymphadenitis following BCG vaccination? Am J Dis Child 1987; 141:1213-4.
21. Hanley SP, Gumb J, MacFarlane JT. Comparison of erythromycin and isoniazid in treatment of adverse reactions to BCG vaccination. Br Med J (Clin Res Ed) 1985; 290:970.
22. FitzGerald JM. Management of adverse reactions to BCG vaccine. Clin Infect Dis 2000; 31:875-6.
23. Marcelino F, Vasconcellos G, Almeida A, Pereira F, Rodriguez F, Dias JA. The Calmette-Guerin bacillus (BCG): an agent to consider in pe-diatric infection [in Portuguese]. Acta Med Port 1996; 9:397-400.
24. Vitkova E, Galliova J, Krepela K, Kubin M. Adverse reactions to BCG. Cent Eur J Public Health 1995; 3:138-41.